Aurobindo Pharma reported its highest-ever quarterly revenue of ₹9,150 crore in Q1 FY27, with net profit surging by 25%. This strong performance was driven by broad-based growth across all its key business segments.
₹9,150 crore
Q1 FY27 Revenue
⏳ Time Machine
How today’s news fits into the bigger picture
2018
US Generics Business Stabilizes
After a period of pricing pressures, Aurobindo Pharma's US generics business began to stabilize, driven by new product launches and market share gains in key therapeutic areas, setting the stage for future revenue growth.
2020-2022
R&D Focus Intensifies
Aurobindo significantly increased its R&D spending, particularly on biosimilars and , aiming to diversify its product mix and move towards higher-value segments. This investment helped build a robust product pipeline for future approvals.
Early 2026
Strategic Market Entries
The company made strategic entries into several emerging markets and expanded its presence in Europe, contributing to a broader revenue base and reducing reliance on single markets. This helped cushion against regional market volatilities.
Q4 FY26
Consistent Performance
Aurobindo Pharma delivered consistent growth in Q4 FY26, setting a positive foundation for the new fiscal year. Revenue and profit figures indicated stable operational performance leading into the record-breaking Q1 FY27.
Last Quarter
Operational Efficiencies Implemented
The company intensified its focus on operational efficiencies and cost management initiatives, which helped in improving margins and contributing to the higher profit growth observed in the current quarter.
Today
Aurobindo Pharma reported its highest-ever quarterly revenue of ₹9,150 crore in Q1 FY27, with profit up 25%.
What happens next?
Aurobindo Pharma is expected to continue focusing on expanding its product portfolio, particularly in injectables and biosimilars, and strengthening its global market presence in upcoming quarters.
Aurobindo Pharma announced robust financial results for the first quarter of fiscal year 2027, achieving a record consolidated revenue of **₹9,150 crore**. The company's profit after tax (PAT) saw a significant jump of **25%** year-on-year. This impressive growth was fueled by strong sales across its various segments, including injectables, US generics, and other emerging markets. The company managed to deliver improved profitability despite a dynamic global operating environment, indicating effective cost management and robust demand for its pharmaceutical products. This quarter's performance sets a positive tone for the rest of the financial year.
💭 If you're wondering…
Injectables are medicines administered directly into the body using a needle, bypassing the digestive system. They often include complex formulations, biosimilars, and vaccines, typically commanding higher margins than oral solid generics due to their complexity and sterile manufacturing requirements.
Did this story help?
Official sources
Knowledge Chain — tap a concept